-
A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy, Safety, and Regimen Selection
-
HER2 Expression and Axillary Metastasis in Treatment-Naïve Early Breast Cancer
-
Chemo‐Immunotherapy, a Combination Approach for the Treatment of HER2‐Positive Breast Cancer in a Mouse Model
-
Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer
-
Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
-
Postoperative Complications Following Neoadjuvant Therapy Across Different Oncoplastic Breast Surgery Techniques: A Retrospective Comparative Study in Breast Cancer Patients
-
Abemaciclib in HR+, HER2− Breast Cancer: A Narrative Review of the Clinical Evidence
-
HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies
-
Artificial Intelligence-Driven Quantitative HER2 Scoring and Spatial Bystander Effect Modeling for ADC Response Stratification in HER2-Low Breast Cancer
-
Clinicians’ Perspectives on the Impact of Different Attributes of Androgen Receptor Pathway Inhibitors on Prostate Cancer Treatment Preferences and Compliance in Mexico
-
The clinical impact of androgens in endometrial cancer: cancer promoter or suppressor?
-
Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer
-
Microenvironmental Cues That Regulate Cancer Cell Dormancy in Estrogen‐Receptor Positive and Triple‐Negative Breast Cancer Cell Lines
-
Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices
-
Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer
-
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study
-
RAP80 Expression in Breast Cancer and Its Relationship with Apoptosis in Breast Cancer Cells [Retraction]
-
HER2 Overexpression in Invasive Breast Carcinoma in the Democratic Republic of Congo and its Association with Selected Clinicopathological Characteristics
-
Research Progress of HER2 in Cervical Carcinoma
-
TOMM40/FADS2 Expression Ratio Predicts the Sensitivity to mTOR Inhibitors in Triple‐Negative Breast Cancer
-
Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data
-
Identification of an Immune Cell Gene Signature for Predicting Response and Prognosis in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
-
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France
-
Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives
